Vancomycin Area under the Curve and Pharmacokinetic Parameters during the First 24 Hours of Treatment in Critically Ill Patients using Bayesian Forecasting
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Currently, the achievement of the target area under the curve (AUC)/ minimum inhibitory concentration ratio during the first 24 - 48 h of treatment is associated with reduced 30-day mortality and greater microbiological eradication in patients with methicillin-resistant Staphylococcus aureus bacteremia. This study aimed to determine the AUC and pharmacokinetic parameters on the first day of vancomycin administration based on the Bayesian theorem to optimize the dosing regimen in critically ill patients. Materials and Methods: This retrospective study included participants meeting the following criteria: 1) ≥18 years old; 2) receipt of at least one dose of vancomycin; 3) measurement of 2 vancomycin serum concentrations during the first 24 h of treatment; and 4) an intensive care unit admission, mechanical ventilator use, or an Acute Physiology and Chronic Health Evaluation II score >15 points. The AUC on day 1 of treatment and the estimated vancomycin pharmacokinetic parameters were measured using PrecisePK software based on the Bayesian theorem. Results: We obtained 132 vancomycin concentrations from 66 patients. The vancomycin pharmacokinetic parameters were as follows: AUC0-24, 571.09 (± standard deviation [SD] 188.62) mg/L·h; clearance (CL), 2.97 (± SD 1.81) L/h; volume of distribution (Vd), 50.60 (± SD 13.91) L; elimination rate constant, 0.062 (± SD 0.039) h−1; and half-life, 18.19 (± SD 15.96) h. Focusing on the vancomycin loading dose, AUC0-24 400 - 600 was achieved in 41.7, 46.1, 44.4, and 26.3% of patients with loading doses of <20, 20 – 24.9, 25 – 30, and >30 mg/kg, respectively. Whereas AUC0-24 ≥521 was achieved in 50, 50, 77.8, and 84.2% of patients with loading doses of <20, 20 – 24.9, 25 – 30, and >30 mg/kg, respectively. The CL of vancomycin was correlated with creatinine CL, whereas the Vd of vancomycin was significantly correlated with age and body weight. Conclusion: This study revealed that the higher Vd and CL values on the first day of vancomycin therapy were found in critically ill patients. Additionally, a higher vancomycin loading dose (25 – 30 mg/kg) might be required to achieve target of AUC0-24 during early phase of administration for critically ill patients.
Abstract
Background: Currently, the achievement of the target area under the curve (AUC)/ minimum inhibitory concentration ratio during the first 24 - 48 h of treatment is associated with reduced 30-day mortality and greater microbiological eradication in patients with methicillin-resistant Staphylococcus aureus bacteremia. This study aimed to determine the AUC and pharmacokinetic parameters on the first day of vancomycin administration based on the Bayesian theorem to optimize the dosing regimen in critically ill patients. Materials and Methods: This retrospective study included participants meeting the following criteria: 1) ≥18 years old; 2) receipt of at least one dose of vancomycin; 3) measurement of 2 vancomycin serum concentrations during the first 24 h of treatment; and 4) an intensive care unit admission, mechanical ventilator use, or an Acute Physiology and Chronic Health Evaluation II score >15 points. The AUC on day 1 of treatment and the estimated vancomycin pharmacokinetic parameters were measured using PrecisePK software based on the Bayesian theorem. Results: We obtained 132 vancomycin concentrations from 66 patients. The vancomycin pharmacokinetic parameters were as follows: AUC0-24, 571.09 (± standard deviation [SD] 188.62) mg/L·h; clearance (CL), 2.97 (± SD 1.81) L/h; volume of distribution (Vd), 50.60 (± SD 13.91) L; elimination rate constant, 0.062 (± SD 0.039) h−1; and half-life, 18.19 (± SD 15.96) h. Focusing on the vancomycin loading dose, AUC0-24 400 - 600 was achieved in 41.7, 46.1, 44.4, and 26.3% of patients with loading doses of <20, 20 – 24.9, 25 – 30, and >30 mg/kg, respectively. Whereas AUC0-24 ≥521 was achieved in 50, 50, 77.8, and 84.2% of patients with loading doses of <20, 20 – 24.9, 25 – 30, and >30 mg/kg, respectively. The CL of vancomycin was correlated with creatinine CL, whereas the Vd of vancomycin was significantly correlated with age and body weight. Conclusion: This study revealed that the higher Vd and CL values on the first day of vancomycin therapy were found in critically ill patients. Additionally, a higher vancomycin loading dose (25 – 30 mg/kg) might be required to achieve target of AUC0-24 during early phase of administration for critically ill patients.
참고문헌 (20)
- Turner NA, "Methicillin-resistant Staphylococcus aureus : an overview of basic and clinical research", Nat Rev Microbiol, 17, pp.203~218 (2019)
- Hassoun A, "Incidence, prevalence, and management of MRSA bacteremia across patient populations-a review of recent developments in MRSA management and treatment", Crit Care, 21, pp.211~ (2017)
- Vestergaard M, "Antibiotic resistance and the MRSA problem", Microbiol Spectr, 7 (2019)[DOI]
- Drennan PG, "The dosing and monitoring of vancomycin : what is the best way forward", Int J Antimicrob Agents, 53, pp.401~407 (2019)
- Avent ML, "Optimising antimicrobial therapy through the use of Bayesian dosing programs", Int J Clin Pharm, 41, pp.1121~1130 (2019)
- Lodise TP, "Vancomycin exposure in patients with methicillin-resistant Staphylococcus aureus bloodstream infections: how much is enough?", Clin Infect Dis, 59, pp.666~675 (2014)
- Bakke V, "Vancomycin levels are frequently subtherapeutic in critically ill patients : a prospective observational study", Acta Anaesthesiol Scand, 61, pp.627~635 (2017)
- Baptista JP, "Augmented renal clearance in septic patients and implications for vancomycin optimisation", Int J Antimicrob Agents, 39, pp.420~423 (2012)
- Rybak M, "Therapeutic monitoring of vancomycin in adult patients : a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists", Am J Health Syst Pharm, 66, pp.82~98 (2009)
- Rybak MJ, "Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections : A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists", Am J Health Syst Pharm, 77, pp.835~864 (2020)
- Turner RB, "Review and validation of bayesian dose-optimizing software and equations for calculation of the vancomycin area under the curve in critically ill patients", Pharmacotherapy, 38, pp.1174~1183 (2018)
- Neely MN, "Are vancomycin trough concentrations adequate for optimal dosing", Antimicrob Agents Chemother, 58, pp.309~316 (2014)
- Katip Bpharm W, "Initial dosage regimen of vancomycin for septic shock patients : a pharmacokinetic study and Monte Carlo simulation", J Med Assoc Thai, 97, pp.1209~1219 (2014)
- Heffernan AJ, "Vancomycin population pharmacokinetics for adult patients with sepsis or septic shock: are current dosing regimens sufficient?", Eur J Clin Pharmacol, 75, pp.1219~1226 (2019)
- Roberts JA, "Vancomycin dosing in critically ill patients : robust methods for improved continuous-infusion regimens", Antimicrob Agents Chemother, 55, pp.2704~2709 (2011)
- Smits A, "Factors impacting unbound vancomycin concentrations in neonates and young infants", Eur J Clin Microbiol Infect Dis, 37, pp.1503~1510 (2018)
- Purwonugroho TA, "Population pharmacokinetics of vancomycin in Thai patients", Sci World J, 2012, pp.762649~ (2012)
- Kovacevic T, "Population pharmacokinetic model of vancomycin based on therapeutic drug monitoring data in critically ill septic patients", J Crit Care, 55, pp.116~121 (2020)
- Tsai D, "Optimised dosing of vancomycin in critically ill Indigenous Australian patients with severe sepsis", Anaesth Intensive Care, 46, pp.374~380 (2018)
- Chattaweelarp T, "Is early monitoring better? Impact of early vancomycin exposure on treatment outcomes and nephrotoxicity in patients with methicillin-resistant Staphylococcus aureus infections", Antibiotics(Basel), 9, pp.672~ (2020)